After claiming an FDA de novo nod in August, Abbott (NYSE: ABT) said it plans to launch its Libre Duo dual-analyte sensor in the U.S. this December. The roll out of the new continuous glucose monitor, which also tracks ketone levels to safeguard against diabetic ketoacidosis, will come after its international debut set for this […]
Abbott Laboratories
Abbott partners with Berry Street to add nutrition coaching to Lingo
Abbott (NYSE: ABT) is teaming up with Berry Street to offer dietitian support programs to Lingo users. Wearers of the over-the-counter continuous glucose monitor can now sign up for personalized nutrition coaching linked to their data trends, and schedule virtual one-on-one appointments with registered and insurance-covered dietitians. At the same time, Berry Street users will […]
Famed marathoner uses Abbott glucose sensor for training
Kenyan long-distance runner Eliud Kipchoge is using a glucose sensor modeled after Abbott Laboratories’ FreeStyle Libre glucose monitor to optimize his training regimen. The sensor, known as the Libre Sense Glucose Sport Biosensor, is the first device intended to help athletes track blood sugar rather than people with diabetes. Kipchoge, who set a world record […]
Abbott’s FreeStyle Libre 3 receives CE Mark
Abbott (NYSE:ABT) has won the CE Mark in the European Union for its next-generation FreeStyle Libre 3 continuous glucose monitoring system. Officials at Abbott boast that the Libre 3 technology includes a super small, thin sensor. It’s the size of two U.S. pennies stacked together and able to accurately provide real-time glucose readings over 14 days […]
Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes
Two major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) — announced today that they’ve inked a non-exclusive patent cross-license agreement related to diabetes treatment tech. The companies said the agreement will allow them to focus on innovation while avoiding the distraction of potential legal disagreements. The deal could be but another example of […]
Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech
Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT) as the lead investor. “We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release today. […]
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated […]
European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds
Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]
Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech
Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported. According to the deal, Abbott will provide Bigfoot with the next-gen version of its FreeStyle Libre continuous […]
Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]
